1. Home
  2. TSLX vs IMCR Comparison

TSLX vs IMCR Comparison

Compare TSLX & IMCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Sixth Street Specialty Lending Inc.

TSLX

Sixth Street Specialty Lending Inc.

HOLD

Current Price

$18.54

Market Cap

1.8B

Sector

Finance

ML Signal

HOLD

Logo Immunocore Holdings plc

IMCR

Immunocore Holdings plc

HOLD

Current Price

$30.30

Market Cap

1.7B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TSLX
IMCR
Founded
2010
2008
Country
United States
United Kingdom
Employees
N/A
N/A
Industry
Investment Managers
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.8B
1.7B
IPO Year
2011
2016

Fundamental Metrics

Financial Performance
Metric
TSLX
IMCR
Price
$18.54
$30.30
Analyst Decision
Buy
Buy
Analyst Count
9
12
Target Price
$21.72
$61.82
AVG Volume (30 Days)
1.5M
355.0K
Earning Date
05-14-2026
05-15-2026
Dividend Yield
11.24%
N/A
EPS Growth
N/A
30.39
EPS
1.81
N/A
Revenue
N/A
$249,428,000.00
Revenue This Year
N/A
$14.39
Revenue Next Year
$1.92
$8.19
P/E Ratio
$10.08
N/A
Revenue Growth
N/A
43.05
52 Week Low
$16.99
$23.15
52 Week High
$25.17
$40.71

Technical Indicators

Market Signals
Indicator
TSLX
IMCR
Relative Strength Index (RSI) 46.00 37.61
Support Level $16.99 N/A
Resistance Level $22.46 $34.86
Average True Range (ATR) 0.57 1.43
MACD 0.12 -0.23
Stochastic Oscillator 83.52 12.86

Price Performance

Historical Comparison
TSLX
IMCR

About TSLX Sixth Street Specialty Lending Inc.

Sixth Street Specialty Lending Inc is a specialty finance company focused on providing flexible, fully committed financing solutions to middle market companies located in the United States of America. It partners with companies across a variety of industries and excel at providing creative solutions to companies with complex business models that may have limited access to capital. The company seeks to generate current income in U.S.-domiciled middle-market companies through direct originations of senior secured loans and, to a lesser extent, originations of mezzanine and unsecured loans and investments in corporate bonds and equity securities.

About IMCR Immunocore Holdings plc

Immunocore Holdings PLC is a commercial-stage biotechnology company. Using its ImmTAX platform, the company is developing a deep pipeline in multiple therapeutic areas, including clinical stage programs in oncology and infectious disease, pre-clinical programs in autoimmune disease, and earlier pre-clinical programs across three therapeutic areas. The company's main product, KIMMTRAK, is used for the treatment of unresectable or metastatic uveal melanoma (mUM). The other drug candidates in its pipeline include Brenetafusp, IMC-P115C, IMC-T119C, IMC-R117C, IMC-S118AI, IMC-U120AI, and others, being developed as a potential treatment for various oncology, infectious, and autoimmune diseases.

Share on Social Networks: